D. Boral Capital reaffirmed their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN – Free Report) in a report released on Tuesday,Benzinga reports. The firm currently has a $14.00 target price on the stock. Several other analysts also recently issued reports on NRSN. Wall Street Zen raised NeuroSense Therapeutics from a “sell” rating to a […]

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $38.00 target price on the stock. Other analysts also recently issued reports about the company. Stifel Nicolaus increased their price target on Dyne Therapeutics from $36.00 to […]

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $23.00 target price on the stock. A number of other research firms also recently issued reports on IBRX. Piper Sandler reiterated an “overweight” rating and issued […]

D. Boral Capital reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $19.00 price target on the stock. TRVI has been the topic of several other reports. Oppenheimer increased their target price on shares of Trevi Therapeutics […]